Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen: Apr 1, 2008

Premium
In an article published on March 25, entitled “Asuragen to Launch New Assay for FFPE Sample Profiling Next Month,” there are inaccuracies in certain statements attributed to Michael Wilson, a senior scientist at Asuragen, relating to regulatory requirements associated with patient sample acquisition (see BAN 3/25/2008).
 
Asuragen told BioArray News last week that it follows a policy that anyone considering working with samples of human origin consults with regulatory officials at their institutions and/or the appropriate federal agencies prior to initiating any sample acquisition or recruitment. 
 
Additionally, Asuragen clarified that it will be launching a service for analyzing gene expression using FFPE samples and does not intend for this service to be used for clinical diagnosis.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.